Attracting one of med-tech’s most accomplished executives, Aldevron has named Kevin Ballinger as Chief Executive Officer, effective July 13, 2020. Aldevron’s co-founder, Michael Chambers, has been named Executive Chairman of the board. Chambers initiated the transition to allow him to focus on innovation, corporate strategy and working with clients and industry thought leaders to develop new technologies that enable genetic medicine. Ballinger will assume day-to-day operational leadership of Aldevron, facilitating the company’s rapid growth.
Genprex, Inc. (NASDAQ: GNPX), is collaborating with Aldevron to secure GMP plasmid DNA manufacturing capacity for Genprex's Oncoprex™ gene therapy portfolio.
The manufacturing program supports upcoming clinical trials, including Oncoprex™ in combination with Tagrisso®, which has received FDA Fast Track Designation. The collaboration with Aldevron will enable full commercial scale plasmid DNA manufacturing capabilities.
Partnership with Harvard scientists at Mass. Eye and Ear and Mass General supports AAV based gene therapies to produce SARS-CoV-2 vaccine
Aldevron is excited to announce our partnership with MEEI to support its manufacturing of an experimental vaccine for clinical studies for its AAVCOVID vaccine program.
Aldevron, the leading plasmid DNA manufacturing company, has expanded its leadership team by appointing Dr. James Brown President of its Research Grade nucleic acids business unit.
Aldevron, a global leader in the custom development and manufacture of plasmid DNA, proteins, mRNA and antibodies for the biotech industry, has hired Vijay Surapaneni as its Vice President of Biomanufacturing Operations. This is a new position and is a part of the senior management team.
Aldevron, a global leader in the custom development and manufacture of plasmid DNA, protein, mRNA and antibodies for the biotech industry, is hosting its second Breakthrough Symposium with the theme “Pioneering Biotech,” September 28-30, 2020, in Fargo, N.D., home to Aldevron’s headquarters and main campus.
FARGO, N.D. (February 12, 2019)—Aldevron, a global leader in the custom development and manufacture of plasmid DNA, proteins, mRNA and antibodies to the biotech industry, announced today the addition of DasherGFP® (green fluorescent protein) mRNA to its off-the-shelf, product portfolio.
In June of 2019, Aldevron announced its massive 14-acre campus expansion. The construction began with a groundbreaking ceremony in August of 2019, launching the buildout of the campus’ second GMP manufacturing facility. This 189,000 square-foot, two-story building is slated to increase Aldevron’s GMP and GMP-Source production capacity up to 10 times its current output. In December of 2019, a major milestone was reached when structural steel beams were installed (pictured).
Aldevron client and partner, Calviri, testing vaccine to prevent cancer in trial using 800 dogs
Aldevron has the privilege of working with thousands of clients trying to solve the world’s biggest health challenges and cancer is at the top of the list. Finding a preventative therapy has long been the goal. Our partner, Calviri, is testing a vaccine in a canine trial that could lead to a treatment for humans.
Aldevron, Nature Technology Corporation team up to offer Nanoplasmids™ for gene therapy manufacturing
Aldevron has announced the immediate availability of NanoplasmidsTM and antibiotic-free RNA-OUT technology for use in gene therapy manufacturing. Through a license agreement with Nature Technology Corporation (NTC), Aldevron can now provide its clients the option of using NTC’s plasmid technology to provide a more efficient system for manufacturing viral vectors used in gene and cell therapy.